Truist Financial Cuts Disc Medicine (NASDAQ:IRON) Price Target to $83.00

Disc Medicine (NASDAQ:IRON) had its price objective reduced by Truist Financial from $114.00 to $83.00 in a research report released on Friday morning,Benzinga reports. Truist Financial currently has a buy rating on the stock.

IRON has been the subject of several other reports. TD Cowen reiterated a “buy” rating on shares of Disc Medicine in a research note on Friday, December 19th. Raymond James Financial reaffirmed a “market perform” rating on shares of Disc Medicine in a report on Thursday, January 15th. Cantor Fitzgerald decreased their price objective on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. Wells Fargo & Company lowered their target price on shares of Disc Medicine from $109.00 to $78.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 17th. Finally, Wedbush cut their price target on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a research note on Tuesday, February 17th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $102.00.

Disc Medicine Stock Down 1.9%

Shares of IRON opened at $66.62 on Friday. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of -11.12 and a beta of 0.87. Disc Medicine has a 52 week low of $30.82 and a 52 week high of $99.50. The stock’s 50-day moving average price is $74.43 and its 200-day moving average price is $75.62. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, beating the consensus estimate of ($1.69) by $0.07. The company had revenue of ($19.88) million for the quarter, compared to analysts’ expectations of $0.15 million. On average, sell-side analysts predict that Disc Medicine will post -4.07 EPS for the current year.

Insider Activity

In related news, COO Jonathan Yen-Wen Yu sold 3,231 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total value of $203,100.66. Following the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $3,414,806.64. This represents a 5.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Pamela Stephenson sold 5,531 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total value of $347,678.66. Following the sale, the insider directly owned 80,998 shares of the company’s stock, valued at approximately $5,091,534.28. This trade represents a 6.39% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 285,114 shares of company stock worth $24,937,862. 3.64% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IRON. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Disc Medicine during the fourth quarter valued at about $33,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Disc Medicine during the 3rd quarter worth approximately $38,000. KBC Group NV acquired a new stake in Disc Medicine in the 4th quarter valued at approximately $80,000. CWM LLC raised its position in Disc Medicine by 213.5% in the second quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after purchasing an additional 711 shares during the period. Finally, Avanza Fonder AB raised its position in Disc Medicine by 54.0% in the third quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock valued at $110,000 after purchasing an additional 585 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.

Trending Headlines about Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Beat on quarterly results — Disc reported Q4 and full‑year 2025 results with EPS of ($1.62), beating consensus (($1.69)) and provided a business update; the small earnings beat is a short‑term positive signal for execution and guidance clarity. Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst target lowered but rating sustained — Truist cut its price target from $114 to $83 but kept a “buy” rating, signalling continued analyst confidence in the longer‑term thesis despite reduced near‑term expectations. Truist lowers price target to $83
• Neutral Sentiment: Insider sale by CFO — CFO Jean M. Franchi sold 353 shares at ~$69; the sale is small (0.49% reduction in her holdings) and appears routine rather than a clear signal of negative private information. CFO insider sale filing
• Neutral Sentiment: Short‑interest report is inconclusive — a MarketBeat entry shows anomalous/zero short interest data for February (days‑to‑cover 0.0), so there’s no clear short‑squeeze or elevated short pressure signal from this report.
• Negative Sentiment: Restructuring after FDA response — Disc’s board approved a restructuring following an FDA response, implying a regulatory/setback event that prompted corporate changes; this raises near‑term execution and timeline uncertainty for pipeline programs. Disc Medicine Implements Restructuring Following FDA Response
• Negative Sentiment: Investor litigation alert — Pomerantz LLP announced an investigation into Disc Medicine, which can increase legal risk, potential distraction, and perceived governance concerns among investors. Pomerantz investigates Disc Medicine

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.